STOCK TITAN

Calidi Biotherapeutics (CLDI) Stock News, Jul-Dec 2023

CLDI NYSE

Calidi Biotherapeutics develops targeted genetic medicines for cancer using systemically delivered virotherapy. Its RedTail platform is designed to selectively target tumors, remodel the tumor microenvironment, and express therapeutic genetic payloads at tumor sites while limiting peripheral exposure.

Recurring CLDI news covers RedTail research presentations, CLD-401 oncology data, IL-15 superagonist payload work, in situ T-cell engager approaches, regulatory preparation, manufacturing and clinical-development partnerships, financing activity, and periodic financial results. Company updates also address pipeline expansion, including RedTail-based programs such as CLD-501 for TROP2-targeted T-cell engagement in solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.50%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.55%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.19%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
635.00%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.66%
Tags
conferences

FAQ

What is the current stock price of Calidi Biotherapeutics (CLDI)?

Calidi Biotherapeutics (CLDI) last closed at $0.5273.

What is the market cap of Calidi Biotherapeutics (CLDI)?

The market cap of Calidi Biotherapeutics (CLDI) is approximately $1.8M.